Spravato is the first FDA approved ketamine medication for treatment resistant depression and is covered by most insurance. Spravato is a nasal spray, administered at Integrated Psych under the care of a provider.

Treatment resistant depression is defined as the failure of three to five oral antidepressant medications. Meaning the patient tried three to five different medications, under the supervision of a qualified provider, for an adequate amount of time and did not see a reduction in symptoms.

Spravato is administered twice a week for four weeks or weekly for eight to twelve weeks.